Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
Delayed Quote. Delayed Nyse - 10/23 04:10:00 pm
49.81 USD   -1.33%
10/23QIAGEN NV : Independant Research remains a Sell rating
MD
10/14QIAGEN NV : Kepler Cheuvreux maintains a Buy rating
MD
10/13QIAGEN NV : Jefferies remains Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

QIAGEN N.V.: Resignation of Chairman of the Supervisory Board

share with twitter share with LinkedIn share with facebook
08/21/2020 | 12:45pm EDT

DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Personnel
QIAGEN N.V.: Resignation of Chairman of the Supervisory Board

21-Aug-2020 / 17:43 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc Announcement according to Art. 17 Market Abuse Regulation

Resignation of Chairman of the Supervisory Board

Venlo, The Netherlands, August 21, 2020 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that Dr. Håkan Björklund, Chairman of the Supervisory Board, has resigned from office as Chairman of the Supervisory Board with immediate effect and has left the Supervisory Board. Dr. Björklund was appointed as member of the Supervisory Board of QIAGEN in March 2017 and served as Chairman since June 2018.

Lawrence A. Rosen has been elected by the Supervisory Board as new Chairman of the Supervisory Board. Mr. Rosen has been a member of the Supervisory Board since 2013.

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

ISIN: NL0012169213

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

Contacts QIAGEN N.V.:

Corporate Communications

John Gilardi, Tel: +49 2103 29 11711; john.gilardi@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

 


21-Aug-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Phone: +31 7735566 - 00
Fax: +31 77 35566-58
E-mail: qiagen@qiagen.com
Internet: www.qiagen.com
ISIN: NL0012169213
WKN: A2DKCH
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX
EQS News ID: 1121897

 
End of Announcement DGAP News Service

1121897  21-Aug-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1121897&application_name=news&site_id=zonebourse
© EQS 2020

share with twitter share with LinkedIn share with facebook
All news about QIAGEN N.V.
10/23QIAGEN NV : Independant Research remains a Sell rating
MD
10/14QIAGEN NV : Kepler Cheuvreux maintains a Buy rating
MD
10/13QIAGEN NV : Jefferies remains Neutral
MD
10/13QIAGEN N : reports strong preliminary results for third quarter of 2020
BU
10/13QIAGEN N.V. : QIAGEN reports strong preliminary results for third quarter of 202..
EQ
10/09QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
10/05QIAGEN : to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies..
BU
09/18QIAGEN NV : Warburg Research reiterates its Neutral rating
MD
09/17QIAGEN N : fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR..
BU
09/15QIAGEN NV : DZ Bank reiterates its Neutral rating
MD
More news
Financials (USD)
Sales 2020 1 802 M - -
Net income 2020 326 M - -
Net Debt 2020 1 017 M - -
P/E ratio 2020 35,6x
Yield 2020 -
Capitalization 11 394 M 11 394 M -
EV / Sales 2020 6,89x
EV / Sales 2021 5,93x
Nbr of Employees 5 200
Free-Float 92,9%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 55,82 $
Last Close Price 49,81 $
Spread / Highest target 32,5%
Spread / Average Target 12,1%
Spread / Lowest Target -23,7%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.47.37%11 394
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830